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Background: Data on the renal safety of Tenofovir (TDF) in Low and Middle Income Countries (LMICs) is scarce. We
compared development of various forms of renal impairment with use of TDF-containing antiretroviral therapy
(ART) between a cohort from the Institute of Infectious Diseases (IID) Pune, Western India and the Royal Free
Hospital (RFH) London, UK.
Methods: This is a retrospective analysis of change in estimated glomerular filtration rates (eGFRs) at 6, 12 and
24 months post TDF initiation using the Modification of Diet in Renal Disease (MDRD) equation. In people living
with Human Immunodeficiency virus (PLHIV) with pre-TDF eGFR > 90 ml/min/1.73 m2 time to development of and
factors associated with progression to eGFR < 60 ml/min/1.73 m2 were calculated using standard survival methods.
Results: A total of 574 (59% Caucasian) at the RFH, and 708 (100% Indian ethnicity) PLHIV from IID were included.
Baseline median eGFR were similar; RFH 102 (IQR 89, 117), IID 100 (82, 119). At 24 months, mean (SD) decline in
eGFR was -7(21) at RFH (p < 0.0001) and -7(40) at IID (p = 0.001). Amongst those with pre-TDF eGFR > 90 ml/min/1.73 m2
PLHIV at IID were more likely to develop an eGFR < 60 ml/min/1.73 m2 (aHR = 7.6 [95% CI 3.4, 17.4] p < 0.0001) and had a
faster rate of progression estimated using Kaplan Meier methods. Risk factors included age (per 10 years older: aHR = 2.21
[1.6, 3.0] p < 0.0001) and receiving concomitant ritonavir boosted Protease Inhibitor (PI/r) (aHR = 2.4 [1.2, 4.8] p = 0.01).
Conclusions: There is higher frequency of treatment limiting renal impairment events amongst PLHIV receiving TDF in
Western India. As TDF scale up progresses, programs need to develop capacity for monitoring and treatment of renal
impairment associated with TDF.
Keywords: Tenofovir, Nephrotoxicity, IndiaBackground
First line antiretroviral treatment (ART) regimens in Low
and Middle Income Countries (LMICs) of non nucleoside
reverse trancriptase inhibitor (NNRTI) with thymidine
analogue nucleoside reverse transcriptase inhibitors
(tNRTIs) are associated with numerous long term toxicities
[1]. The World Health Organization (WHO) has recom-
mended phasing out stavudine (d4T) and using tenofovir
(TDF) as component of first line treatment regimens [2].* Correspondence: sanjaypujari@gmail.com
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unless otherwise stated.Amongst those failing first-line tNRTI regimens, TDF
with ritonavir boosted PI (PI/r) is recommended as a
second line regimen.
Tenofovir based regimens are associated with excellent
efficacy and safety in clinical trials [3]. However, these
studies have been done in High Income Countries (HICs)
and data on their effectiveness and safety in LMICs is
limited [4-7]. Tenofovir has been associated with renal
toxicity amongst 1-2% of people living with Human
Immunodeficiency Virus (PLHIV) but higher proportion
of patients demonstrate a fall in estimated Glomerular
Filtration Rate (eGFR) [8]. Traditional risk factors aretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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antiretrovirals, although not everybody with these risk
factors develops renal adverse events [9]. In Sub-saharan
Africa, severe eGFR impairment was infrequent over 4 years
irrespective of the use of TDF [10]. The authors of this
study conclude that TDF based first line ART can be safely
given even without renal monitoring in these settings.
There is no published data on the incidence of TDF
induced renal dysfunction amongst PLHIV in India. We
determined and compared the incidence of and risk factors
for renal impairment associated with TDF use amongst
PLHIVs accessing care in a HIC and LMIC setting.
Methods
Setting
People living with HIV accessing care at two clinics:
HIC-the Royal Free Hospital (RFH), London, UK and
LMIC- Institute of Infectious Diseases (IID), Pune Western
India were included
Design
This is a retrospective study comparing renal outcomes
amongst PLHIV at these two sites. Data was abstracted
from clinic electronic and paper records. Approval for
the study was given by Chairman’s approval letter from
the Royal Free Ethics Committee while at Institute of
Infectious Diseases all HIV positive persons provide
consent on Ethics committee (Chest Research Foundations
Independent Ethics Committee, Pune India) approved form
mentioning that data collected during the course of care
would be used for research analysis. Patient details were
annonymized for data analysis.
Study population
All HIV-1 positive adults initiating TDF for the first time
between 1st January 2007 to 31st December 2009 with at
least one follow up eGFR measurement were included in
the final analysis. At both sites renal evaluations (serum
creatinine, urine analysis, serum phosphate, electrolytes)
are performed at baseline and every 3 to 6 months after
initiation of TDF as standard of care and whenever
clinically indicated. At IID PLHIV pay out of pocket
for subsidized antiretrovirals (ARVs) and laboratory tests,
while National Health Services (NHS) provides for the
same at RFH.
Measurements
The eGFR was estimated using the Modification of Diet
in Renal Disease (MDRD) equation. However, all analyses
were repeated using the Cockroft-Gault (CG) formula and
the results were consistent. A recent study amongst Indians
has documented optimal performance of MDRD equation
for estimating eGFR, while the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation showedmarked bias at higher eGFRs [11]. Information on demo-
graphic variables at the time of initiating TDF was sum-
marised. An eGFR >90/ml/min/1.73 m2 is considered
normal while eGFR <60 ml/min/1.73 m2 considered as
decreased. Partial Fanconi’s syndrome was diagnosed by
the presence of one or more of the following: normogly-
cemic glycosuria, hypophosphatemia, tubular acidosis and
hypouricemia [12]. CD4 counts and Plasma viral loads were
determined by flow cytometry and PCR (Roche Taqman,
Lower limit of quantification <40 copies/ml) respectively.
Treatment limiting renal toxicity was defined as any renal
impairment leading to permanent discontinuation of TDF,
including those who demonstrated a declining trend to an
eGFR of less than 60 ml/min/1.73 m2.
Data analysis
Characteristics of PLHIV at the time of starting TDF
were summarised according to clinical centre. The eGFR
at the time of initiating TDF (Baseline; measured within
the 6 months previous to initiating TDF), and 6, 12, 18
and 24 months after starting TDF were calculated by
creating a window 3 months either side of the time point
of interest, and considering the eGFR that occurred
within the window closest to this time point. As the
eGFR measurements were suitable normally distributed,
the eGFR value at each time point, as well as the change
in eGFR from baseline were summarised using the mean
and standard deviation (SD). Changes over time within
and between centres were compared using paired and
unpaired t-tests respectively at two pre-defined time
points of 6 and 24 months post-TDF initiation.
Finally, the subset of PLHIV with an eGFR >90 ml/min/
1.73 m2 when initiating TDF were considered. Time to
development of eGFR < 60 ml/min/1.73 m2 was calculated
using standard survival methods, with individuals who did
not experience the event being censored at the time of the
last available eGFR measurement. Factors associated with
time to eGFR < 60 ml/min/1.73 m2 were investigated using
Cox proportional hazards models. The variables included
in this models included site, age, gender, use of con-
comitant PI/r, pre-TDF and nadir CD4 count, time since
HIV diagnosis, and ever receiving PI/r prior to receipt
of TDF. No formal adjustments were made for multiple
testing. All analyses were performed using SAS version
9.3 (SAS Institute Inc, Cary, NC).
Results
Baseline demographics
A total of 574 and 708 HIV positive individuals from RFH
and IID respectively initiating TDF based ART were
included in the final analysis (Table 1). All PLHIV at
IID were of Indian ethnicity whilst approximately 60%
at RFH were Caucasian. Approximately 75% PLHIV at
IID were using TDF in an NNRTI based (EFV, NVP)
Table 1 Patient characteristics at time of starting tenofovir
Royal Free Pune
N 574 (100.0) 708 (100.0)
Age (years) Median (IQR) 41 (35, 47) 38 (34, 45)
Gender Male 439 (76.5) 537 (75.8)
Female 135 (23.5) 171 (24.2)
Ethnicity White 339 (59.1) -
Black 161 (28.1) -
Indian - 708 (100.0)
Other 74 (12.9) -
Risk for HIV transmission MSM 333 (58.0) -
Heterosexual 224 (39.0) -
Other 17 (3.0) -
CD4 count (cells/mm3) Median (IQR) 348 (230, 525) N = 571 242 (118, 395) N = 657
HIV RNA viral load (log copies/ml) Median (IQR) 4.2 (<1.7, 5.0) N = 536 N/A
ART-naïve when started TDF Yes 314 (54.7) 307 (43.4)
No 260 (45.3) 401 (56.6)
Time since first ART at time of starting TDF (weeks) Median (IQR) 368 (217, 545) N = 260 162 (66, 274) N = 400
Other ARVs in regimen Emtricitabine 530 (97.2) 641 (90.5)
Lamivudine 28 (4.9) 61 (8.6)
Zidovudine 10 (1.7) 62 (8.8)
Didanosine 1 (0.2) 1 (0.1)
Abacavir 22 (3.8) 2 (0.2)
Lopinavir 152 (26.5) 49 (6.9)
Atazanavir 88 (15.3) 125 (17.7)
Darunavir 35 (6.1) 0 (0.0)
Saquinavir 28 (4.9) 1 (0.1)
Fos-amprenavir 16 (2.8) 0 (0.0)
Nelfinavir 2 (0.4) 0 (0.0)
Ritonavir 308 (53.6) 181 (25.6)
Efavirenz 211 (36.8) 341 (48.2)
Nevirapine 50 (8.7) 183 (25.9)
Etravirine 7 (1.2) 0 (0.0)
T20 1 (0.2) 0 (0.0)
Raltegravir 13 (2.3) 0 (0.0)
Maraviroc 2 (0.4) 0 (0.0)
Stavudine 13 (1.8)
Indinavir 6 (0.9)
Baseline eGFR Median (IQR) 102 (89, 117) 100 (82, 119)
Baseline creatinine Median (IQR) 77 (68, 87) 79 (62, 88)
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boosted PI-based regimen. Approximately half of the
PLHIV at each site were ARV naive at TDF initiation.
At both the sites EFV was the commonest NNRTI used
(36.8% at RFH and 48.2% at IID) while LPV/r (26.5%)
and ATV/r (17.5%) were the main PIs used at RFH andIID respectively. Median CD4 count at baseline was
lower at IID (242 cells/mm3 vs 348 cells/mm3). Meas-
urement of viral load prior to initiation of ART is not
part of routine care at IID. Baseline median eGFR were
normal and similar at both sites (102 ml/min/1.73 m2
and 100 ml/min/1.73 m2 at RFH and IID respectively).
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eGFR < 90 ml/min/1.73 m2 at baseline (Table 2).
Changes in renal function
Changes in eGFR over follow up at the two sites are
summarized in Table 2. There was a statistically significant
decline in eGFR from baseline at 6 and 24 months at both
the sites, however there was not a statistically significant
difference in eGFR decline between sites. People living with
HIV at both sites had an average decline in eGFR of 7 ml/
min/1.73 m2 at 24 months post TDF-initiation.
Amongst individuals with pre-TDF eGFR > 90 ml/min/
1.73 m2, PLHIV at IID were more likely than the RFH
to develop an eGFR < 60 ml/min/1.73 m2 (adjusted
hazard ratio [aHR]: 7.6 p < 0.0001) (Table 3 and Figure 1).
Independent risk factors associated with progression to
eGFR < 60 ml/min/1.73 m2 included age (per 10 years
older aHR: 2.21) and receiving concomitant PI/r (aHR: 2.4).
Interestingly, neither CD4 counts at eGFR estimation nor
CD4 nadir were associated with significant eGFR decline.
An eGFR < 60 ml/min/1.73 m2 developed amongst 41
PLHIV at IID and 8 individuals at RFH. Fifteen PLHIV
at IID developed partial Fanconi’s syndrome (8 with
concomitant NNRTI and 7 with boosted PI). Fifty-nine
(8.3%) individuals developed treatment limiting toxicity at
IID (41with eGFR < 60 ml/min/1.73 m2, 15 partial Fanconi
syndrome and 3 acute kidney injury) and 8 individuals
developed treatment limiting toxicity (all with eGFR <
60 ml/min/1.73 m2) at RFH. Twenty-one (35.5%) of these
PLHIV had co-morbidities (Hypertension-11, Diabetes -9,
chronic HCV-1), however we did not perform any formalTable 2 GFR (ml/min/1.73 m2) results using MDRD over follow
Baseline 6 mth
Royal Free patients
Number with measure 574 514
GFR Mean (SD) 104 (25) 100 (2
Change from baseline - −4 (1
GFR <90 150 (26.1) 169 (3
GFR < 60 10 (1.7) 7 (1.4
GFR < 30 1 (0.2) 1 (0.2
P-value for change from baseline <0.00
IID, Pune patients
Number with measure 702 439
GFR Mean (SD) 105 (35) 97 (2
Change from baseline −6 (3
GFR <90 254 (36.2) 193 (4
GFR < 60 38 (5.4) 28 (6
GFR < 30 2 (0.3) 0 (0.0
P-value for change from baseline <0.00
P-value for comparison of centres 0.46adjustment analysis due to small sample size. The charac-
teristics of 15 PLHIV with partial Fanconi’s syndrome have
been summarized in Table 4.
Discussion
To our knowledge, this is the first comparison of TDF
associated renal dysfunction, amongst PLHIV accessing
care in HIC and LMIC clinics. The WHO has recom-
mended scaling up TDF based first line ARV regimens
in LMICs. While we and others have demonstrated the
effectiveness of TDF based first line regimens there is
limited data on the safety, especially renal and bone
toxicity in LMICs [13,14].
Although the change in eGFR from baseline were similar
amongst PHIV at both sites, we found significantly higher
frequency of treatment limiting renal toxicity and a higher
risk of developing an eGFR < 60 ml/min/1.73 m2 associated
with TDF in Western India. Weight was not included as a
covariate in analysis, as when the results were repeated
using the CG formula (which includes weight), consistent
results were obtained However, weight/creatinine ratio has
been associated with renal toxicity and perhaps current rec-
ommended dose of TDF may be high for Indians [15,16].
At both sites significant risk factors associated with
reduction in eGFR were age and concomitant PI/r. Use
of concomitant PI/r has been associated with higher risk
of renal toxicity in individuals taking TDF [17]. Inhibition
of Multi-Resistance Protein (MRP-4) efflux channels in
the proximal convoluted tubules by ritonavir may contrib-
ute to this [18]. Renal dysfunction has been documented
to be more common when TDF is combined with ATV/rup
s 12 mths 18 mths 24 mths
468 364 273
3) 99 (22) 97 (21) 97 (25)
9) −6 (18) −6 (19) −7 (21)
2.9) 178 (38.0) 128 (35.2) 110 (40.3)
) 8 (1.7) 9 (2.5) 11 (4.0)
) 2 (0.4) 2 (0.6) 0 (0.0)
01 <0.0001
391 366 302
8) 96 (28) 98 (29) 96 (31)
9) −7 (38) −8 (40) −7 (40)
4.0) 195 (49.9) 165 (45.1) 144 (47.7)
.4) 27 (6.9) 32 (8.7) 23 (7.6)
) 2 (0.5) 2 (0.6) 2 (0.7)
01 0.001
0.76
Table 3 Factors associated with HIV positive persons developing (single measurement) eGFR of <60 ml/min/1.73 m2
who had baseline eGFR > 90 /ml/min1.73/m2
Univariate Multivariate
HR 95% CI p HR 95% CI p
Centre Pune 4.87 2.28, 10.38 <0.0001 7.65 3.36, 17.41 <.0001
RF 1.00 - 1.00 -
Age Per 10 years older 1.85 1.43, 2.40 <.00001 2.21 1.61, 3.05 <.0001
Gender Female 1.63 0.89, 2.99 0.12 1.72 0.90, 3.29 0.10
Male 1.00 - 1.00 -
Receiving PI Yes 1.01 0.57, 1.79 0.97 2.40 1.21, 4.76 0.01
No 1.00 - 1.00 -
CD4 count Per 100 cells 1.01 0.90, 1.13 0.89 1.04 0.89, 1.20 0.65
Time since diagnosis Per year longer 0.98 0.92, 1.04 0.46 1.00 0.92, 1.07 0.92
CD4 nadir Per 100 cells 0.94 0.78, 1.14 0.55 0.99 0.79, 1.23 0.91
Ever received a PI before TDF Yes 0.76 0.32, 1.78 0.52 0.77 0.28, 2.15 0.62
No 1.00 - 1.00 -
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may have accounted for the difference in this study [19].
When TDF is used with PI/r in second line regimens in
RLS, monitoring for renal toxicity is warranted. This also
argues for using TDF in first line regimens with NNRTIs.
Risk factors associated with treatment limiting nephro-
toxicity in our study included Diabetes, Hypertension,
and receipt of concomitant nephrotoxic medications. ItPune:   448 414 365 29
RFH:   424            399 339 27
Figure 1 Time to progression to eGFR < 60 m/min/1.73 m2 amongst t
development of eGFR < 60 ml/min/1.73 m2 as determined by MDRD amon
eGFR > 90 ml/min/1.73 m2 at IID, Pune (red) and Royal Free Hospital, UK (bluewould be prudent to perform frequent renal monitoring
or to avoid the use of TDF in the presence of these risk
factors. Predictors of significant nephrotoxicity such as
pre-existing renal impairment, older age, advanced HIV
disease, vasculometabolic disease, low body weight have
been well documented [16,20]. In addition careful renal
monitoring is warranted amongst HIV positive individuals
with acute inter-current illnesses.5 174 103
0 172 103
hose with baseline eGFR > 90 ml/min/1.73 m2. Legend: Time to
gst HIV positive individuals initiating Tenofovir with a baseline
). The difference across the centres is statistically significant (p < 0.0001).
Table 4 Characteristics of HIV positive individuals with
partial Fanconi’s syndrome
Variable
Lab features
Normoglycemic glycosuria with hypophosphatemia 11
Normoglycemic glycosuria with hypokalemia and
metabolic acidosis
1
Normoglycemic glycosuria and hypouricemia 1
Hypophosphatemia 2
Medain age (range) 54.3 (42-67)
Gender
Male 9
Median duration of TDF, weeks (range) 92 (24-188)
Co-morbidities
None 13
Hypertension 2
Concomitant ARV
NVP 5
EFV 3
ATV/r 5
LPV/r 2
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renal toxicity seen at IID included progression to
eGFR < 60 ml/min/1.73 m2, Acute Kidney Injury and
partial Fanconi’s syndrome. Two of the HIV positive
individuals were diagnosed as having partial Fanconi’s
syndrome on the basis of only profound hypophosphatemia
(serum phopshorus <1.5 mg/dl) and one patient with
hypouricemia (Serum uric acid 1.9 mg/dl) and normo-
glycemic glycosuria. Although this is controversial, we
did not have access to other tests for assessing tubular
dysfunction like aminoaciduria, tubular proteinuria,
and fractional excretion of phosphate. Partial Fanconi’s
syndrome may present without eGFR decline, hence high
clinical suspicion (e.g. proximal muscle weakness) and
routine monitoring for glycosuria (triggering blood glucose
determination to confirm normoglycemic glycosuria) is
needed. Other components like aminoaciduria, tubular
proteinuria and tubular acidosis needed to define Fanconi’s
syndrome may not be routinely available in LMICs.
Our study has several limitations aside from the retro-
spective observational design. We have reported eGFR
estimated using the MDRD formula, although consistent
results were obtained when in a sensitivity analysis using
the CG formula. The small sample size precludes interpret-
ation of the incidence and adjustments for risk factors asso-
ciated with renal impairment have not been included in the
analysis. We have used a single eGFR < 60 ml/min/1.73 m2
estimation in the analysis that can indicate incident CKD,
AKI or creatinine blips or laboratory errors. Additionallywe have not included urine analysis data, although glyco-
suria (normoglycemic glcosuria) was used as a trigger to
investigate for partial Fanconi syndrome. Comparing two
different populations at two different settings with differ-
ing standards of practice also limits external validity.
Conclusions
In summary, renal dysfunction was more commonly
associated with the use of TDF based regimens in
Western India compared to PLHIV in the UK. As TDF
based regimens are being scaled up in LMICs, early
identification and management of various forms of
TDF induced renal injury would need renal monitoring
(especially those with background risk factors for renal
disease) and physician training. Exploring alternative
strategies like lowering TDF dose and use of alternative
formulations like TDF alefenamide (TAF) also needs to
be urgently studied in these settings.
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